Abstract
Within the last few years we have treated still more types of cancer with immune checkpoint inhibitors - anti-cytotoxic T-lymphocyte-associated-4 antibodies and anti-program-med cell death 1/anti-programmed cell death ligand 1 antibodies. A unique set of side effects called immune related adverse events irAEs may occur during treatment. Although severe irAEs remain rare they can become life-threatening. Early detection of irAEs and initiation of relevant treatment are therefore crucial to reduce the risk of long-term seque-lae. We provide a detailed overview of irAEs and recommendations for treatment according to established guidelines.
| Bidragets oversatte titel | Immunotherapy is cancer treatment with a novel side-effect profile |
|---|---|
| Originalsprog | Dansk |
| Artikelnummer | V05170365 |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 179 |
| Antal sider | 5 |
| ISSN | 0041-5782 |
| Status | Udgivet - 2017 |
Emneord
- Antibodies, Monoclonal/adverse effects
- Antineoplastic Agents, Immunological/adverse effects
- CTLA-4 Antigen/antagonists & inhibitors
- Chemical and Drug Induced Liver Injury/etiology
- Drug-Related Side Effects and Adverse Reactions/diagnostic imaging
- Endocrine System Diseases/chemically induced
- Gastrointestinal Diseases/chemically induced
- Humans
- Immunotherapy/adverse effects
- Lung Diseases/chemically induced
- Mobile Applications
- Neoplasms/drug therapy
- Practice Guidelines as Topic
- Programmed Cell Death 1 Receptor/antagonists & inhibitors
- Skin Diseases/chemically induced
- Tomography, X-Ray Computed
FN’s Verdensmål
Dette resultat bidrager til følgende verdensmål
